Skip to main content
Equibles
KRYS logo

KRYS · Krystal Biotech, Inc. · Webcasts, Transcripts & Audio

Track KRYS — free

Use KRYS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KRYS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$305.23 -0.45 (-0.15%) At close · Nov 13 Play latest call Q2 2026 earnings call transcript
S&P 400 member Russell 2000 member Rebalance outlook locked
Market Cap
$9.05B
Shares
29.63M
Volume · Nov 13 110.29K Avg daily vol (3M) 280.28K

Krystal Biotech, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Krystal Biotech, Inc. (KRYS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)

Embed Krystal Biotech, Inc. earnings calls on your site

Pick a widget, match your page, then paste the code where it should appear.

Widget
Theme
Accent color Pro

Match your site's colors with Pro. The Equibles credit stays on every plan.

Embed code 

                    
The widget credits Equibles and keeps the link below it on every plan.

                

            


            

                Preview
                
            

        

        
    

    




    


    
    

        

            
            
            
            
        

            

                
                    
                    
                    
                    
            

        
        
    


    
    

            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY26 · Q3

                    
2026-11-02

                


                
                

                    
Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call

                    

                    

                


                
                

                        

                                

                                    
Revenue

                                    
$127.34M

▲ 30.2% YoY                                

                                

                                    
Diluted EPS

                                    
$2.05

▼ 22.9% YoY                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY26 · Q2

                    
2026-08-03

                


                
                

                    
Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                International Vyjuvec launch momentum
                                U.S. commercial performance and penetration
                                Pricing and reimbursement negotiations
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$119.22M

▲ 24.1% YoY                                

                                

                                    
Diluted EPS

                                    
$1.79

▲ 38.8% YoY                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Conference
                    

                        
Investor event

                    
2026-05-13

                


                
                

                    
Krystal Biotech, Inc. (KRYS) May 13, 2026 Conference Transcript

                    

                    

                


                
                

                        No reported result — non-financial event
                


                
                

                    Audio
                    Transcript
                    Slides
                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY26 · Q1

                    
2026-05-04

                


                
                

                    
Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                Pricing and reimbursement negotiations in Europe
                                Vyjuvec U.S. commercial performance
                                Oncology program KB803
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$116.36M

▲ 31.9% YoY                                

                                

                                    
Diluted EPS

                                    
$1.83

▲ 52.5% YoY                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY25 · Q4

                    
2026-02-17

                


                
                

                    
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                Geographic Expansion
                                VYJUVEC Commercial Performance
                                Ophthalmology / Ocular Program Dosing Changes
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$107.11M*

▲ 17.5% YoY                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-K                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY25 · Q3

                    
2025-11-03

                


                
                

                    
Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                Geographic expansion (Europe and Japan)
                                VYJUVEK commercial launch momentum
                                Pipeline development and clinical readouts
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$97.80M

▲ 16.6% YoY                                

                                

                                    
Diluted EPS

                                    
$2.66

▲ 192.3% YoY                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY25 · Q2

                    
2025-08-04

                


                
                

                    
Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                Vyjuvec launch and U.S. commercial progress
                                Patient compliance dynamics
                                Aesthetics / KB304 / Jun subsidiary
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$96.04M

▲ 36.6% YoY                                

                                

                                    
Diluted EPS

                                    
$1.29

▲ 143.4% YoY                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY25 · Q1

                    
2025-05-06

                


                
                

                    
Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                VYJUVEK U.S. commercial performance
                                VYJUVEK global expansion (EU/Japan)
                                Clinical pipeline readouts in 2025
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$88.18M

▲ 94.9% YoY                                

                                

                                    
Diluted EPS

                                    
$1.20

▲ 3900% YoY                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY24 · Q4

                    
2024-12-31

                        
Date not confirmed

                


                
                

                    
Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                VYJUVEK U.S. launch
                                Lung delivery platform pipeline
                                Ophthalmology (B-VEC for DEB eye lesions)
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$91.14M*

▲ 116.3% YoY                                

                                

                                    Rev · 7q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-K                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY24 · Q3

                    
2024-11-04

                


                
                

                    
Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                VYJUVEK launch and revenue
                                Ex-U.S. launches and reimbursement
                                Clinical pipeline readouts
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$83.84M

▲ 879.9% YoY                                

                                

                                    
Diluted EPS

                                    
$0.91

▼ 67.4% YoY                                

                                

                                    Rev · 7q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY24 · Q2

                    
2024-08-05

                


                
                

                    
Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings Call

                    

                    

                


                
                

                        

                                

                                    
Revenue

                                    
$70.28M

                                

                                

                                    
Diluted EPS

                                    
$0.53

                                

                                

                                    Rev · 6q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY24 · Q1

                    
2024-05-06

                


                
                

                    
Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                Patient Compliance and Real-World Experience
                                VYJUVEK U.S. Commercial Launch
                                International Expansion
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$45.25M

                                

                                

                                    
Diluted EPS

                                    
$0.03

                                

                                

                                    Rev · 5q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY23 · Q4

                    
2024-02-26

                


                
                

                    
Krystal Biotech, Inc. (KRYS) Q4 2023 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                VYJUVEK US launch trajectory and revenue
                                Reimbursement, J-code and gross-to-net dynamics
                                Pipeline and platform breadth
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$42.14M*

                                

                                

                                    Rev · 4q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-K                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY23 · Q3

                    
2023-11-06

                


                
                

                    
Krystal Biotech, Inc. (KRYS) Q3 2023 Earnings Call Transcript

                    

                    

                


                
                

                        

                                

                                    
Revenue

                                    
$8.56M

                                

                                

                                    
Diluted EPS

                                    
$2.79

                                

                                

                                    Rev · 4q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
    

    

        
Showing 1–14 of 14 webcasts

    

    

    
    


        

    

        

            

                Key facts
                    
                        CIK
                        1711279
                    
                    
                        CUSIP
                        501147102
                    
                    
                        13F (30d)
                        365 filings
                        333 filers
                    
                    
                    
                         Visit website
                        
                    
                    
                         Investor relations